Themis Medicare fixes Sep 23 record date for FY26 final dividend

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Record date for FY26 final dividend fixed as September 23, 2026
  • Dividend payout requires approval at the 56th AGM on September 30, 2026
  • Disclosure made under SEBI Listing Regulations Regulation 42
  • Board meeting confirming the date was held on September 18, 2026
powered bylight_fuzz_icon
51273671

*this image is generated using AI for illustrative purposes only.

Themis Medicare has fixed September 23, 2026, as the record date for determining shareholder eligibility for the final dividend for the financial year ended March 31, 2026.

The Board of Directors approved the record date in its meeting held on September 18, 2026. The actual dividend payout remains subject to approval by members at the company’s 56th Annual General Meeting (AGM), scheduled for September 30, 2026.

Regulatory Disclosure

The company made the disclosure pursuant to Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was issued by the Corporate Relationship Department to the listing exchanges.

Dinesh S. Patel, Chairman and Director of Themis Medicare Limited, signed the communication.

Historical Stock Returns for Themis Medicare

1 Day5 Days1 Month6 Months1 Year5 Years
+3.44%-6.13%+19.10%+64.66%+0.31%+22.55%

What is the proposed dividend per share amount, and how does it compare to Themis Medicare's payout history in previous fiscal years?

How might the approval of this final dividend impact the company's free cash flow and capital allocation strategy for the upcoming fiscal year?

Are there any pending regulatory approvals or litigation risks that could potentially delay or alter the dividend distribution post-AGM?

Themis Medicare updates Company Secretary and RTA contact emails

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Themis Medicare Limited updated its Company Secretary and RTA email IDs on August 17, 2026. The new CS email is suresh.savaliya@themismedicare.com , and the RTA email is investor.helpdesk@in.mpms.mufg.com . The update was communicated to BSE and NSE by Chairman Dinesh S. Patel.

powered bylight_fuzz_icon
48512984

*this image is generated using AI for illustrative purposes only.

Themis Medicare has updated the electronic contact details for its compliance officer and registrar to ensure seamless investor communication. The company informed the Bombay Stock Exchange and National Stock Exchange of India Limited on August 17, 2026, regarding the change in the Company Secretary’s registered email address.

The existing email ID for Sangameshwar Iyer has been replaced with a new address for Suresh Savaliya. All future correspondence regarding investor relations and compliance matters should be directed to the new ID. This administrative update ensures that regulatory filings and investor queries are routed correctly within the corporate governance framework.

Contact Details Update

The company also updated the email address for its Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. Investors and stakeholders are advised to use the new RTA email ID for all share-related inquiries and documentation requests.

Contact Type: New Email Address
Company Secretary suresh.savaliya@themismedicare.com
RTA (MUFG Intime) investor.helpdesk@in.mpms.mufg.com

The notification was signed by Dinesh S. Patel, Chairman and Director of Themis Medicare Limited. The company’s corporate office is located in Goregaon, Mumbai, while its registered office remains in Vapi, Gujarat. These changes do not impact the company’s financial operations or strategic direction but serve to maintain accurate records with the exchanges.

Historical Stock Returns for Themis Medicare

1 Day5 Days1 Month6 Months1 Year5 Years
+3.44%-6.13%+19.10%+64.66%+0.31%+22.55%

Could the change in Company Secretary signal a broader restructuring of Themis Medicare's corporate governance or compliance team?

How might this administrative update impact the efficiency of investor relations and regulatory filing timelines for the company?

Are there any pending regulatory inquiries or compliance issues that might have prompted this specific update in contact details?

More News on Themis Medicare

1 Year Returns:+0.31%